Iron-targeting antitumor activity of gallium compounds and novel insights into triapine®-metal complexes

Antioxidants and Redox Signaling

Volumn 18, Issue 8, 2013, Pages 956-972

  Chitambar, Christopher R ^a   Antholine, William E ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; ALPHA INTERFERON; BORTEZOMIB; CHELATING AGENT; ETOPOSIDE; FLUDARABINE; G 4544; GALLIUM; GALLIUM MALTOLATE; GALLIUM NITRATE; GEMCITABINE; GLUTATHIONE; GLUTATHIONE DISULFIDE; HEMOJUVELIN; HYDROXYUREA; IFOSFAMIDE; IRON; KP 46; METAL COMPLEX; METALLOTHIONEIN; MITOGUAZONE; PACLITAXEL; PYRIDINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; RIBONUCLEOTIDE REDUCTASE; THIOSEMICARBAZONE DERIVATIVE; TRANSFERRIN; TRANSFERRIN RECEPTOR; TRIS(8 QUINOLATO)GALLIUM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BLADDER CANCER; BONE METABOLISM; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL METABOLISM; CELL PROLIFERATION; CELL PROTECTION; CONTINUOUS INFUSION; CYTOTOXICITY; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; ENDOCYTOSIS; HOMEOSTASIS; HUMAN; HYPERCALCEMIA; IRON METABOLISM; IRON TRANSPORT; LARGE CELL LYMPHOMA; LIVER CELL CARCINOMA; MANTLE CELL LYMPHOMA; MITOCHONDRION; NONHODGKIN LYMPHOMA; NONHUMAN; OXIDATION REDUCTION STATE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; UROGENITAL TRACT CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; COORDINATION COMPLEXES; GALLIUM; HUMANS; IRON; IRON CHELATING AGENTS; MOLECULAR MIMICRY; NEOPLASMS; PYRIDINES; THIOSEMICARBAZONES;

EID: 84873871117     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.4880     Document Type: Review

References (145)

1. Adamson RH, Canellos GP, and Sieber SM. Studies on the antitumor activity of gallium nitrate (NSC-l5200) and other group IIIa metal salts. Cancer Chemother Rep 59: 599-610, 1975.
2. Agrawal KC, Booth BA, Moore EC, and Sartorelli AC. Antitumor effects of transition metal chelates of 1-for-mylisoquinoline thiosemicarbazone. Proc Am Assoc Cancer Res 15: 1974, 1974.
3. Allamneni KP, Burns RB, Gray DJ, Valone FH, Bucalo LR, and Sreedharan SP. Gallium maltolate treatment results in transferrin-bound gallium in patient serum. Proc Am Assoc Cancer Res 45: 230 (abstract 1013), 2004.
4. Anghileri LJ and Robert J. Radiogallium as a probe for magnesium-binding sites. Magnes-Bull 2: 197-200, 1982.
5. Antholine WE and Taketa F. Effects of 2-formylpyridine monothiosemicarbazonato copper II on red cell components. J Inorg Biochem 20: 69-78, 1984.
6. Antholine WE, Taketa F, Wang JT, Manoharan PT, and Rifkind JM. Interaction between bound cupric ion and spin-labeled cysteine beta-93 in human and horse hemoglobins. J Inorg Biochem 25: 95-108, 1985.
7. Arion VB, Jakupec MA, Galanski M, Unfried P, and Kep-pler BK. Synthesis, structure, spectroscopic and in vitro antitumour studies of a novel gallium(III) complex with 2-acetylpyridine 4N-dimethylthiosemicarbazone. J Inorg Bio-chem 91: 298-305, 2002.
8. Beer SM, Taylor ER, Brown SE, Dahm CC, Costa NJ, Runswick MJ, and Murphy MP. Glutaredoxin 2 catalyzess the reversible oxidation and glutathionylation of mito-chondrial membrane thiol proteins: implications for mito-chondrial redox regulation and antioxidant defense. J Biol Chem 279: 47939-47951, 2004.
9. Berggren MM, Burns LA, Abraham RT, and Powis G. Inhibition of protein tyrosine phosphatase by the antitumor agent gallium nitrate. Cancer Res 53: 1862-1866, 1993.
10. Bernstein LR. Mechanisms of therapeutic activity for gallium. Pharmacol Rev 50: 665-682, 1998.
11. Bernstein LR, Tanner T, Godfrey C, and Noll B. Chemistry and pharmacokinetics of gallium maltolate, a compound with high oral gallium bioavailability. Metal-Based Drugs 7: 33-47, 2000.
12. Bernstein LR, van der Hoeven JJM, and Boer RO. Hepa-tocellular detection by gallium scan and subsequent treatment by gallium maltolate: rationale and case study. Anit-cancer Agents Med Chem 11: 585-590, 2011.
13. Berry JP, Poupon MF, Galle S, and Escaig F. Role of lyso-somes in gallium concentration by mammalian tissues. Biol Cell 51: 43-51, 1984.
14. Blower PJ, Lewis JS, and Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol 23: 957-980, 1996.
15. Bockman R. The effects of gallium nitrate on bone resorp-tion. Semin Oncol 30: 5-12, 2003.
16. Chan SM, Hoffer PB, and Duray P. Inhibition of Gallium-67 uptake in melanoma by an anti-human transferrin receptor monoclonal antibody. J Nucl Med 28: 1303-1307, 1987.
17. Chan-Stier CH, Minkel D, and Petering DH. Reactions of bis(thiosemicarbazonato) copper(II) complexes with tumor cells and mitochondria. Bioinorg Chem 6: 203-217, 1976.
18. Chapuis N, Tamburini J, Green AS, Willems L, Bardet V, Park S, Lacombe C, Mayeux P, and Bouscary D. Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. Leukemia 24: 1686-1699, 2010.
19. Chaston TB, Lovejoy DB, Watts RN, and Richardson DR. Examination of the antiproliferative activity of iron chela-tors: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin Cancer Res 9: 402-414, 2003.
20. Chauhan D, Hideshima T, Mitsiades C, Richardson P, and Anderson KC. Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther 4: 686-692, 2005.
21. Chen D, Frezza M, Shakya R, Cui QC, Milacic V, Verani CN, and Dou QP. Inhibition of the proteasome activity by gallium(III) complexes contributes to their anti prostate tumor effects. Cancer Res 67: 9258-9265, 2007.
22. Chitambar CR. Gallium compounds as antineoplastic agents. Curr Opin Oncol 16: 547-552, 2004.
23. Chitambar CR. Gallium nitrate for the treatment of non-Hodgkin's lymphoma. Expert Opin Investig Drugs 13: 531-541, 2004.
24. Chitambar CR, Boon P, and Wereley JP. Evaluation of transferrin and gallium-pyridoxal isonicotinoyl hydrazone as potential therapeutic agents to overcome lymphoid leukemic cell resistance to gallium nitrate. Clin Cancer Res 2: 1009-1015, 1996.
25. Chitambar CR, Matthaeus WG, Antholine WE, Graff K, and O'Brien WJ. Inhibition of leukemic HL60 cell growth by transferrin-gallium: effects on ribonucleotide reductase and demonstration of drug synergy with hydroxyurea. Blood 72: 1930-1936, 1988.
26. Chitambar CR, Narasimhan J, Guy J, Sem DS, and O'Brien WJ. Inhibition of ribonucleotide reductase by gallium in mu-rine leukemic L1210 cells. Cancer Res 51: 6199-6201, 1991.
27. Chitambar CR and Purpi DP. A novel gallium compound synergistically enhances bortezomib-induced apoptosis in mantle cell lymphoma cells. Leuk Res 34: 950-953, 2010.
28. Chitambar CR, Purpi DP, Woodliff J, Yang M, and Wereley JP. Development of gallium compounds for treatment of lymphoma: gallium maltolate, a novel hydroxypyrone gallium compound induces apoptosis and circumvents lymphoma cell resistance to gallium nitrate. J Pharmacol Exp Ther 322: 1228-1236, 2007.
29. Chitambar CR and Sax D. Regulatory effects of gallium on transferrin-independent iron uptake by human leukemic HL60 cells. Blood 80: 505-511, 1992.
30. Chitambar CR and Seligman PA. Effects of different transferrin forms on transferrin receptor expression, iron uptake and cellular proliferation of human leukemic HL60 cells: mechanisms responsible for the specific cytotoxicity of transferrin-gallium. J Clin Invest 78: 1538-1546, 1986.
31. Chitambar CR and Wereley JP. Transferrin receptor-dependent and-independent iron transport in gallium-resistant human lymphoid leukemic cells. Blood 91: 4686-4693, 1998.
32. Chitambar CR and Wereley JP. Expression of the hemo-chromatosis (HFE) gene modulates the cellular uptake of 67Ga. J Nucl Med 44: 943-946, 2003.
33. Chitambar CR, Wereley JP, and Haq RU. Synergistic inhibition of T-lymphoblastic leukemic CCRF-CEM cell growth by gallium and recombinant human a-interferon through action on cellular iron uptake. Cancer Res 54: 3224-3228, 1994.
34. Chitambar CR, Wereley JP, Heiman T, Antholine WE, and O'Brien WJ. Cellular adaptation to down-regulated iron transport into lymphoid leukaemic cells: effects on the expression of the gene for ribonucleotide reductase. Biochem J 345: 681-685, 2000.
35. Chitambar CR, Wereley JP, and Matsuyama S. Gallium-induced cell death in lymphoma: role of transferrin receptor cycling, involvement of Bax and the mitochondria, and effects of proteasome inhibition. Mol Cancer Ther 5: 2834-2843, 2006.
36. Chitambar CR, Zahir SA, Ritch PS, and Anderson T. Evaluation of continuous-infusion gallium nitrate and hydroxyurea in combination for the treatment of refractory non-Hodgkin's lymphoma. Am J Clin Oncol 20: 173-178, 1997.
37. Chitambar CR and Zivkovic Z. Inhibition of hemoglobin production by transferrin-gallium. Blood 69: 144-149, 1987.
38. Chitambar CR and Zivkovic Z. Uptake of gallium-67 by human leukemic cells: demonstration of transferrin receptor-dependent and transferrin- independent mechanisms. Cancer Res 47: 3929-3934, 1987.
39. 67Ga by human leukemic HL60 cells. Cancer Res 50: 1484-1487, 1990.
40. Chitambar CR, Zivkovic-Gilgenbach Z, Narasimhan J, and Antholine WE. Development of drug resistance to gallium nitrate through modulation of cellular iron uptake. Cancer Res 50: 4468-4472, 1990.
41. Chua MS, Bernstein LR, Li R, and So SK. Gallium maltolate is a promising chemotherapeutic agent for the treatment of hepatocellular carcinoma. Anticancer Res 26: 1739-1743, 2006.
42. Collery P, Domingo JL, and Keppler BK. Preclinical toxicology and tissue gallium distribution of a novel antitumor gallium compound: tris (8-quinolinolato) gallium (III). An-ticancer Res 16: 687-692, 1996.
43. Collery P, Jakupec MA, Kynast B, and Keppler BK. Pre-clinical and early clinical developemnt of the oral Gallium complex KP46 (FFC11). In: Metal Ions in Biology and Medicine, edited by Alpoim MC, Morais PV, Santos MA, Cris-tovao L, Centeno JA, and Collery P. Paris: John Libbey Eurotext, 2006, pp. 521-524.
44. Cory JG. Role of ribonucleotide reductase in cell division. In: Inhibitors of Ribonucleoside Diphosphate Reductase Activity, edited by Cory JG and Cory AH. New York: Pergamon Press, 1989, pp. 1-16.
45. Davies NP, Rahmanto YS, Chitambar CR, and Richardson DR. Resistance to the antineoplastic agent gallium nitrate results in marked alterations in intracellular iron and gallium trafficking: identification of novel intermediates. J Pharmacol Exp Ther 317: 153-162, 2006.
46. Davis SR and Cousins RJ. Metallothionein expression in animals: a physiological perspective on function. J Nutr 130: 1085-1088, 2000.
47. DeConti RC, Toftness BR, Agrawal KC, Tomchick R, Mead JA, Bertino JR, Sartorelli AC, and Creasey WA. Clinical and pharmacological studies with 5-hydroxy-2-formylpyridine thiosemicarbazone. Cancer Res 32: 1455-1462, 1972.
48. Dreicer R, Propert KJ, Roth BJ, Einhorn LH, and Loehrer PJ. Vinblastine, Ifosfamide, and Gallium Nitrate-an active new regimen in patients with advanced carcinoma of the urothelium. Cancer 79: 110-114, 1997.
49. Einhorn L. Gallium nitrate in the treatment of bladder cancer. Semin Oncol 30: 34-41, 2003.
50. Einhorn LH, Roth BJ, Ansari R, Dreicer R, Gonin R, and Loehrer PJ. Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma. J Clin Oncol 12: 2271-2276, 1994.
51. Engstrom Y, Eriksson S, Jildevik I, Skog S, Thelander L, and Tribukait B. Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits. J Biol Chem 260: 9114-9116, 1985.
52. Engstrom Y and Francke U. Assignment of the structural gene for subunit M1 of human ribonucleotide reductase to the short arm of chromosome 11. Exp Cell Res 158: 477-483, 1985.
53. Enyedy EA, Primik MF, Kowol CR, Arion VB, Kiss T, and Keppler BK. Interaction of Triapine and related thiosemi-carbazones with iron(III)/(II) and gallium(III): a comparative solution equilibrium study. Dalton Trans 40: 5895-5905, 2011.
54. Eriksson S, Gräslund A, Skog S, Thelander L, and Tribukait B. Cell cycle-dependent regulation of mammalian ribonu-cleotide reductase. The S phase-correlated increase in sub-unit M2 is regulated by de novo protein synthesis. J Biol Chem 259: 11695-11700, 1984.
55. Finch RA, Liu MC, Cory AH, Cory JG, and Sartorelli AC. Triapine (3-aminopyridine-2-carboxaldehyde thiosemi-carbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity. Adv Enzyme Regul 39: 3-12, 1999.
56. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de VS, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O'Connor OA, Shi H, Boral AL, and Goy A. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24: 4867-4874, 2006.
57. Foster BJ, Clagett-Carr K, Hoth D, and Leyland-Jones B. Gallium nitrate: the second metal with clinical activity. Cancer Treat Rep 70: 1311-1319, 1988.
58. Gallego B, Kaluderovic MR, Kommera H, Hey-Hawkins E, Paschke R, and Kaluderovic GN. Novel gallium(III) complexes containing phthaloyl derivatives of neutral amino acids with apoptotic activity in cancer cells. J Organomet Chem 694: 2191-2197, 2009.
59. Gallego B, Kaluderovic MR, Kommera H, Paschke R, Hey-Hawkins E, Remmerbach TW, Kaluderovic GN, and Gomez-Ruiz S. Cytotoxicity, apoptosis and study of the DNA-binding properties of bi-and tetranuclear gallium(III) complexes with heterocyclic thiolato ligands. Invest New Drugs 29: 932-944, 2011.
60. Gräslund A, Sahlin M, and Sjöberg B-M. The tyrosyl free radical in ribonucleotide reductase. Environ Health Perspect 64: 139-149, 1985.
61. Green MA, Mathias CJ, Welch MJ, McGuire AH, Perry D, Fernandez-Rubio F, Perlmutter JS, Raichle ME, and Bergmann SR. Copper-62-labeled pyruvaldehyde bis(N4-methylthiosemicarbazonato)copper(II): synthesis and evaluation as a positron emission tomography tracer for cerebral and myocardial perfusion. J Nucl Med 31: 1989-1996, 1990.
62. Habashy HO, Powe DG, Staka CM, Rakha EA, Ball G, Green AR, Aleskandarany M, Paish EC, Douglas MR, Nicholson RI, Ellis IO, and Gee JM. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer Res Treat 119: 283-293, 2010.
63. Hall MD, Brimacombe KR, Varonka MS, Pluchino KM, Monda JK, Li J, Walsh MJ, Boxer MB, Warren TH, Fales HM, and Gottesman MM. Synthesis and structure-activity evaluation of isatin-beta-thiosemicarbazones with improved selective activity toward multidrug-resistant cells expressing P-glycoprotein. J Med Chem 54: 5878-5889, 2011.
64. Hancock CN, Stockwin LH, Han B, Divelbiss RD, Jun JH, Malhotra SV, Hollingshead MG, and Newton DL. A copper chelate of thiosemicarbazone NSC 689534 induces oxida-tive/ER stress and inhibits tumor growth in vitro and in vivo. Free Radic Biol Med 50: 110-121, 2011.
65. Haq RU and Chitambar CR. Modulation of transferrin receptor mRNA by transferrin-gallium in human myeloid HL60 cells and lymphoid CCRF-CEM cells. Biochem J 294: 873-877, 1993.
66. 59Fe uptake by cultured mouse myeloma cells. Cancer Res 37: 3634-3638, 1977.
67. Hata Y, Sandler A, Loehrer PJ, Sledge GW, Jr., and Weber G. Synergism of taxol and gallium nitrate in human breast carcinoma cells: schedule dependency. Oncol Res 6: 19-24, 1994.
68. Hentze MW, Muckenthaler MU, Galy B, and Camaschella C. Two to tango: regulation of Mammalian iron metabolism. Cell 142: 24-38, 2010.
69. Hoffer P. Status of gallium-67 in tumor detection. J Nucl Med 21: 394-398, 1980.
70. Hofheinz RD, Dittrich C, Jakupec MA, Drescher A, Jaehde U, Gneist M, Graf von KN, Keppler BK, and Hochhaus A. Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors-a CESAR study (Central European Society for Anticancer Drug Research-EWIV). Int J Clin Pharmacol Ther 43: 590-591, 2005.
71. Huang ML, Lane DJ, and Richardson DR. Mitochondrial mayhem: the mitochondrion as a modulator of iron metabolism and its role in disease. Antioxid Redox Signal 15: 3003-3019, 2011.
72. Hurd TR, Requejo R, Filipovska A, Brown S, Prime TA, Robinson AJ, Fearnley IM, and Murphy MP. Complex I within oxidatively stressed bovine heart mitochondria is glutathionylated on Cys-531 and Cys-704 of the 75-kDa subunit: potential role of CYS residues in decreasing oxi-dative damage. J Biol Chem 283: 24801-24815, 2008.
73. Jansson PJ, Sharpe PC, Bernhardt PV, and Richardson DR. Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity. J Med Chem 53: 5759-5769, 2010.
74. Kaluderovic MR, Gomez-Ruiz S, Gallego B, Hey-Hawkins E, Paschke R, and Kaluderovic GN. Anticancer activity of dinuclear gallium(III) carboxylate complexes. Eur J Med Chem 45: 519-525, 2010.
75. Kaluderovic MR, Kaluderovic GN, Gomez-Ruiz S, Paschke R, Hemprich A, Kuhling J, and Remmerbach TW. Orga-nogallium(III) complexes as apoptosis promoting antican-cer agents for head and neck squamous cell carcinoma (HNSCC) cell lines. J Inorg Biochem 105: 164-170, 2011.
76. Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, and Pazdur R. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 13: 5291-5294, 2007.
77. Klaassen CD, Liu J, and Choudhuri S. Metallothionein: an intracellular protein to protect against cadmium toxicity. Annu Rev Pharmacol Toxicol 39: 267-294, 1999.
78. Knorr GM and Chitambar CR. Gallium-pyridoxal iso-nicotinoyl hydrazone (Ga-PIH), a novel cytotoxic gallium complex. A comparative study with gallium nitrate. An-ticancer Res 18: 1733-1738, 1998.
79. Kolesar JM, Sachidanandam K, Schelman WR, Eickhoff J, Holen KD, Traynor AM, Alberti DB, Thomas JP, Chitambar CR, Wilding G, and Antholine WE. Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic Resonance. Exp Ther Med 2: 119-123, 2011.
80. Kolesar JM, Schelman WR, Geiger PG, Holen KD, Traynor AM, Alberti DB, Thomas JP, Chitambar CR, Wilding G, and Antholine WE. Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine. J Inorg Bio-chem 102: 693-698, 2008.
81. Kowol CR, Berger R, Eichinger R, Roller A, Jakupec MA, Schmidt PP, Arion VB, and Keppler BK. Gallium(III) and iron(III) complexes of alpha-N-heterocyclic thiosemicarba-zones: synthesis, characterization, cytotoxicity, and interaction with ribonucleotide reductase. J Med Chem 50: 1254-1265, 2007.
82. Kowol CR, Reisner E, Chiorescu I, Arion VB, Galanski M, Deubel DV, and Keppler BK. An electrochemical study of antineoplastic gallium, iron and ruthenium complexes with redox noninnocent alpha-N-heterocyclic chalcogensemi-carbazones. Inorg Chem 47: 11032-11047, 2008.
83. Kowol CR, Trondl R, Heffeter P, Arion VB, Jakupec MA, Roller A, Galanski M, Berger W, and Keppler BK. Impact of metal coordination on cytotoxicity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine) and novel insights into terminal dimethylation. J Med Chem 52: 5032-5043, 2009.
84. Kraker A, Krezoski S, Schneider J, Minkel D, and Petering DH. Reaction of 3-ethoxy-2-oxobutyraldehyde bis(thiosemicarbazonato) Cu(II) with Ehrlich cells. Binding of copper to metallothionein and its relationship to zinc metabolism and cell proliferation. J Biol Chem 260: 13710-13718, 1985.
85. Kratz F, Nuber B, Weis J, and Keppler BK. Synthesis and characterization of potential antitumor and antiviral galli-um(III) complexes of a-(N)-heterocyclic thiosemicarba-zones. Synth React Inorg Met-Org Chem 21: 1601-1615, 1991.
86. Kvaloy S, Langholm R, Kaalhus O, Michaelsen T, Funder-ud S, Foss AA, and Godal T. Transferrin receptor and B-lymphoblast antigen-their relationship to DNA synthesis, histology and survival in B-cell lymphomas. Int J Cancer 33: 173-177, 1984.
87. Larson SM, Rasey JS, Allen DR, Nelson NJ, Grunbaum Z, Harp GD, and Williams DL. Common pathway for tumor cell uptake of Gallium-67 and Iron-59 via a transferrin receptor. J Natl Cancer Inst 64: 41-53, 1980.
88. Leyland-Jones B. Treatment of cancer-related hypercalce-mia: the role of gallium nitrate. Semin Oncol 30: 13-19, 2003.
89. Lovejoy DB, Jansson PJ, Brunk UT, Wong J, Ponka P, and Richardson DR. Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes. Cancer Res 71: 5871-5880, 2011.
90. Lundberg JL and Chitambar CR. Interaction of gallium nitrate with fludarabine and iron chelators: effects on the proliferation of human leukemic HL60 cells. Cancer Res 50: 6466-6470, 1990.
91. 13C NMR spectroscopic study of the binding of hard and soft metal species. J Am Chem Soc 102: 916-924, 1980.
92. Mendes IC, Soares MA, Dos Santos RG, Pinheiro C, and Beraldo H. Gallium(III) complexes of 2-pyridineformamide thiosemicarbazones: cytotoxic activity against malignant glioblastoma. Eur J Med Chem 44: 1870-1877, 2009.
93. Merryweather-Clarke AT, Pointon JJ, Shearman JD, and Robson KJ. Global prevalence of putative haemochroma-tosis mutations. J Med Genet 34: 275-278, 1997.
94. Miller LD, Coffman LG, Chou JW, Black MA, Bergh J, D'Agostino R, Jr., Torti SV, and Torti FM. An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res 71: 6728-6737, 2011.
95. Myers JM, Antholine WE, Zielonka J, and Myers CR. The iron-chelating drug triapine causes pronounced mitochon-drial thiol redox stress. Toxicol Lett 201: 130-136, 2011.
96. Narasimhan J, Antholine WE, and Chitambar CR. Effect of gallium on the tyrosyl radical of the iron-dependent M2 subunit of ribonucleotide reductase. Biochem Pharmacol 44: 2403-2408, 1992.
97. Narasimhan J, Antholine WE, Chitambar CR, and Petering DH. Inhibition of iron uptake in HL60 cells by 2-formylpyridine monothiosemicarbazonato Cu(II). Arch Biochem Biophys 289: 393-398, 1991.
98. Novick SC, Julian TN, Majuru S, Mangelus M, Brown BD, Mehta B, and Warrell RP. Initial phase I clinical and pharmacokinetic assessment of G4544, an oral gallium-containing compound. J Clin Oncol 26: 8592, 2008.
99. Nyholm S, Mann GJ, Johansson AG, Bergeron RJ, Gräslund A, and Thelander L. Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron che-lators. J Biol Chem 268: 26200-26205, 1993.
100. Perchellet EM, Ladesich JB, Collery P, and Perchellet JP. Microtubule-disrupting effects of gallium chloride in vitro. Anticancer Drugs 10: 477-488, 1999.
101. Petering DH. Physicochemical properties of the antitumor agent, 3 ethoxy 2 oxobutyraldehyde bis(thiosemicarbazo-nato) copper(II). Bioinorg Chem 1: 255-271, 1972.
102. Petering DH, Antholine WE, and Saryan LA. Metal complexes as antitumor agents. In: Anticancer and Inter-feron Agents, edited by Ottenbrite RM and Butler GB. New York and Basel: Marcel Dekker, Inc., 1984, pp. 203-246.
103. Petering HG, BuskirkHH, and Underwood GE. The anti-tumor activity of 2-keto-3ethoxybutyraldehyde bis(thiose-micarbazone) and related compounds. Cancer Res 24: 367-372, 1964.
104. Pinnix ZK, Miller LD, Wang W, D'Agostino R, Jr., Kute T, Willingham MC, Hatcher H, Tesfay L, Sui G, Di X, Torti SV, and Torti FM. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med 2: 43-56, 2010.
105. Popovic-Bijelic A, Kowol CR, Lind ME, Luo J, Himo F, Enyedy EA, Arion VB, and Gräslund A. Ribonucleotide reductase inhibition by metal complexes of Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone): a combined experimental and theoretical study. J Inorg Bio-chem 105: 1422-1431, 2011.
106. Poulsen CB, Borup R, Borregaard N, Nielsen FC, Moller MB, and Ralfkiaer E. Prognostic significance of metallothionein in B-cell lymphomas. Blood 108: 3514-3519, 2006.
107. Pro B, Bociek RG, Chitambar CR, Gregory SA, Leonard JP, Smith S, and Novick S. Phase 2 multicenter trial of gallium nitrate in patients with advanced non-Hodgkin's lym-phoma (NHL). Blood 104: 682A, 2004.
108. Rasey JS, Nelson NJ, and Larson SM. Tumor cell toxicity of stable gallium nitrate: enhancement by transferrin and protection by iron. Eur J Cancer Clin Oncol l8: 66l-668, 1982.
109. Richardson DR, Kalinowski DS, Richardson V, Sharpe PC, Lovejoy DB, Islam M, and Bernhardt PV. 2-Acetylpyridine thiosemicarbazones are potent iron chelators and anti-proliferative agents: redox activity, iron complexation and characterization of their antitumor activity. J Med Chem 52: 1459-1470, 2009.
110. Richardson DR, Sharpe PC, Lovejoy DB, Senaratne D, Kalinowski DS, Islam M, and Bernhardt PV. Dipyridyl thiosemicarbazone chelators with potent and selective an-titumor activity form iron complexes with redox activity. J Med Chem 49: 6510-6521, 2006.
111. Richardson DR, Tran EH, and Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 86: 4295-4306, 1995.
112. Roy CN and Enns CA. Iron homeostasis: new tales from the crypt. Blood 96: 4020-4027, 2000.
113. Roy CN, Penny DM, Feder JN, and Enns CA. The hereditary hemochromatosis protein, HFE, specifically regulates transferrin-mediated iron uptake in HeLa cells. J Biol Chem 274: 9022-9028, 1999.
114. Rudnev AV, Foteeva LS, Kowol C, Berger R, Jakupec MA, Arion VB, Timerbaev AR, and Keppler BK. Preclinical characterization of anticancer gallium(III) complexes: solubility, stability, lipophilicity and binding to serum proteins. J Inorg Biochem 100: 1819-1826, 2006.
115. Seidman AD, Scher HI, Heinemann MH, Bajorin DF, Stern-berg CN, Dershaw DD, Silverberg M, and Bosl GJ. Continuous infusion gallium nitrate for patients with advanced refractory urothelial tumors. Cancer 68: 2561-2565, 1991.
116. Seligman PA, Moran PL, Schleicher RB, and Crawford ED. Treatment with gallium nitrate: evidence for interference with iron metabolism in vivo. Am J Hematol 41: 232-240, 1992.
117. Shakya R, Peng F, Liu J, Heeg MJ, and Verani CN. Synthesis, structure, and anticancer activity of galli-um(III) complexes with asymmetric tridentate ligands: growth inhibition and apoptosis induction of cisplatin-resistant neuroblastoma cells. Inorg Chem 45: 6263-6268, 2006.
118. Shao J, Zhou B, Di Bilio AJ, Zhu L, Wang T, Qi C, Shih J, and Yen Y. A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ri-bonucleotide reductase. Mol Cancer Ther 5: 586-592, 2006.
119. Siegel R, Naishadham D, and Jemal A. Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
120. Smith NW, Strutton GM, Walsh MD, Wright GR, Seymour GJ, Lavin MF, and Gardiner RA. Transferrin receptor expression in primary superficial human bladder tumours identifies patients who develop recurrences. Br J Urol 65: 339-344, 1990.
121. Spingarn NE and Sartorelli AC. Synthesis and evaluation of the thiosemicarbazone, dithiocarbazonate, and 2¢-pyraziny-lhydrazone of pyrazinecarboxaldehyde as agents for the treatment of iron overload. J Med Chem 22: 1314-1316, 1979.
122. Straus DJ. Gallium nitrate in the treatment of lymphoma. Semin Oncol 30: 25-33, 2003.
123. Tennant DA, Duran RV, and Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 10: 267-277, 2010.
124. Thelander L and Reichard P. Reduction of ribonucleotides. Ann Rev Biochem 48: 133-158, 1979.
125. Todd PA and Fitton A. Gallium nitrate: a review of its pharmacological properties and therapeutic potential in cancer-related hypercalcemia. Drugs 42: 261-273, 1991.
126. Torti SV and Torti FM. Ironing out cancer. Cancer Res 71: 1511-1514, 2011.
127. Tsui K-H, Feng T-H, Cheng P-L, and Juang H-H. Gallium deregulates mitochondrial aconitase gene in human prostate carcinoma cells. Androl Update 1: 304-312, 2007.
128. Valiahdi SM, Jakupec MA, Marculescu R, and Keppler BK. Tris(8-quinolinolato)gallium(III) Exerts Strong Antiproliferative Effects in Melanoma Cells. Paris: Libbey Eurotext, 2006, pp. 282-286.
129. Vallabhajosula SR, Harwig JF, Siemsen JK, and Wolf W. Radiogallium localization in tumors:Blood binding and transport and the role of transferrin. J Nucl Med 21: 650-656, 1980.
130. Vavere AL and Lewis JS. Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans 4893-4902, 2007.
131. Waalkes TP, Sanders K, Smith RG, and Adamson RH. DNA polymerases of Walker 256 carcinosarcoma. Cancer Res 34: 385-391, 1974.
132. Warrell RP, Jr., Bockman RS, Coonley CJ, Isaacs M, and Staszewski H. Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia. J Clin Invest 73: 1487-1490, 1984.
133. Warrell RP, Jr., Coonley CJ, Straus DJ, and Young CW. Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven-day continuous infusion. Cancer 51: 1982-1987, 1983.
134. Warrell RP, Jr., Danieu L, Coonley CJ, and Atkins C. Salvage chemotherapy of advanced lymphoma with investi-gational drugs: mitoguazone, gallium nitrate and etoposide. Cancer Treat Rep 71: 47-51, 1987.
135. Whitnall M, Howard J, Ponka P, and Richardson DR. A class of iron chelators with a wide spectrum of potent an-titumor activity that overcomes resistance to chemothera-peutics. Proc Natl Acad Sci USA 103: 14901-14906, 2006.
136. Yang DC, Wang F, Elliott RL, and Head JF. Expression of transferrin receptor and ferritin H-chain mRNA are associated with clinical and histopathological prognostic indicators in breast cancer. Anticancer Res 21: 541-549, 2001.
137. Yang M and Chitambar CR. Role of oxidative stress in the induction of metallothionein-2A and heme oxygenase-1 gene expression by the antineoplastic agent gallium nitrate in human lymphoma cells. Free Radic Biol Med 45: 763-772, 2008.
138. Yang M, Kroft SH, and Chitambar CR. Gene expression analysis of gallium-resistant and gallium-sensitive lym-phoma cells reveals a role for metal-responsive transcription factor-1, metallothionein-2A, and zinc transporter-1 in modulating the antineoplastic activity of gallium nitrate. Mol Cancer Ther 6: 633-643, 2007.
139. Yang-Feng TL, Barton DE, Thelander L, Lewis WH, Srini-vasan PR, and Francke U. Ribonucleotide reductase M2 subunit sequences mapped to four different chromosomal sites in humans and mice: functional locus identified by its amplification in hydroxyurea-resistant cell lines. Genomics 1: 77-86, 1987.
140. Yu Y, Kalinowski DS, Kovacevic Z, Siafakas AR, Jansson PJ, Stefani C, Lovejoy DB, Sharpe PC, Bernhardt PV, and Richardson DR. Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide re-ductase inhibitors. J Med Chem 52: 5271-5294, 2009.
141. Yu Y, Kovacevic Z, and Richardson DR. Tuning cell cycle regulation with an iron key. Cell Cycle 6: 1982-1994, 2007.
142. Yu Y, Suryo RY, Hawkins CL, and Richardson DR. The potent and novel thiosemicarbazone chelators di-2-pyridylketone-4, 4-dimethyl-3-thiosemicarbazone and 2-benzoylpyridine-4, 4-dimethyl-3-thiosemicarbazone affect crucial thiol systems required for ribonucleotide reductase activity. Mol Pharmacol 79: 921-931, 2011.
143. Yu Y, Wong J, Lovejoy DB, Kalinowski DS, and Richardson DR. Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Clin Cancer Res 12: 6876-6883, 2006.
144. Yu Z, Persson HL, Eaton JW, and Brunk UT. Intralysosomal iron: a major determinant of oxidant-induced cell death. Free Radic Biol Med 34: 1243-1252, 2003.
145. Zanias S, Papaefstathiou GS, Raptopoulou CP, Papazisis KT, Vala V, Zambouli D, Kortsaris AH, Kyriakidis DA, and Zafiropoulos TF. Synthesis, structure, and antiproliferative activity of three gallium(III) azole complexes. Bioinorg Chem Appl 2010: 168030, 2010.